Member Info for RayPointer

But I do think Cliff could be very busy from now onwards

I think Cliff is a time traveller.
Moving clocks run slow.

So, as I understand it from Inan, it is about protecting all possible ways of arriving at the TCR for a citrullinated epitope.

Is this Lindy just closing loopholes? Perhaps the main Moditope patent does not cover every possible way to target the citrullinated epitopes.

Covidity may hold the key to how fast a Scancell transformation takes place.
I still consider it to be a longshot but who knows with a scientist as brilliant as Lindy leading the project.
If highly potent T Cells plus a range of targets turns out to be the key to defeating Covid19 then IB could overnight become the must have platform for many infections as well as cancer :-)

We are looking ahead but doesn't IB have the potential for many deals. I am talking about the flexibility to go after different targets for different cancer indications and now we are seeing possible widespread use outside cancer.
You could think of IB as the chip and the targets as the software.

YES, sorry I was getting confused with IB.
Let's see what our potato harvester says :-)

Yes, that clarifies the main role of amplivant. Perhaps it has a secondary role when the vaccine/antibody comes into contact with a DC.
Hopefully Burble will comment later.

Yes Inan, it also came as a surprise to me. It sounds as though amplivant is more about delivery than anything else. Perhaps it helps to bind strongly to a specific type of DC. The DC then proceeds to ingest the vaccine/antibody. I don't know if it stays attached to the peptide and then also plays a role in the TCell binding and/or activation. Burble may have the answers.

One thing that I hadn't realised was how easy and cheap it is to manufacture a DNA vaccine compared to other types. It also seems easier to achieve the desired purity.
This is surely a big plus for IB in general and particularly Covidity.

To me the most ingenious facet of IB is the dual presentation to the dendritic cells. It's as though the DC says to itself - "eyup 2 people have told me about this antigen, I think I need to get cracking and do something about this".
Also I hadn't realised that amplivant helps the vaccine find its way to the DC.

Thanks Burble and Inan for some great posts.

I'll look forward at that post Burble.

What is it about scientists and coffee?

Lse has share price above ask.
Looks odd. Another lse bug?

The thing about TA indicators is that the vast majority of them indicate what has already happened. There is no reliable "this is a turning point" indicator. If there was we would all be billionaires. :-)

Hi Chester

https://www.lse.co.uk/rns/SCLP/proposed-capital-raise-1enlhyfpz9m8ehn.html

"Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence."

ATB

From memory, they have sold a few in the past.

Inan has forgotten to add a link in the past.
Just an inadvertant ommission IMO.
Nowt but a storm in a teacup.

I am quoting best case scenario of course :-)

Hi Cars

Co-incidentally I have just finished re-listening to Cliff's 30 minute proactive presentation.
The figure quoted by crumbs are for 1 glycans mab for 1 cancer indication. Cliff confirmed this in the Q and A session.
So we may see n times these figures where n = 4 (no of mabs) x average number of indications per mab
I have excluded mab2811 in this since this may be treated differently.

On top of that we may have follow up deals for Avidimab to be applied to any mab developed by these 3 companies.
And, as I understand it, this is not just cancer mabs.

Yes, we may be entering a period of consolidation or even retracement to a support level.
Who knows?
We may have to await a news item to spark the next leg up.